Jubilant Life up on USFDA nod for Rizatriptan Benzoate OD tablets

Rizatriptan Benzoate OD (Orally Disintegrating) Tablets are the generic version of Merck's Maxalt-MLT OD tablets

Shares of Jubilant Life Sciences were up over 2% at Rs 396 after the company said it has received Abbreviated New Drug Application (ANDA) final approval from the USFDA for Rizatriptan Benzoate OD (Orally Disintegrating) Tablets, in dosages of 5mg and 10mg.

Rizatriptan Benzoate OD (Orally Disintegrating) Tablets are the generic version of Merck's Maxalt-MLT Orally Disintegrating, 5 mg and 10 mg tablets, which is indicated for the acute treatment of migraine in adults and in paediatric patients, the company said in a release.

As on June 30, 2015, Jubilant Life Sciences had a total of 815 filings for formulations of which 389 have been approved in various regions globally, the release added.

The stock opened at Rs 391 and touched a high of Rs 404. At 1:20pm, over 1.5 million shares were traded on both the stock exchanges.